Inmune Bio (INMB) Other Operating Expenses (2019 - 2025)
Inmune Bio (INMB) posted Other Operating Expenses of $16.5 million for Q2 2025, up 13777.31% sequentially from $119000.0 in Q2 2024, and up 13777.31% YoY from N/an in Q2 2024.
Inmune Bio (INMB) Other Operating Expenses (2019 - 2025) Analysis & Trends
Inmune Bio has reported Other Operating Expenses for 6 years, with the latest figure at $16.5 million in Q2 2025.
- Quarterly Other Operating Expenses rose 13777.31% year-over-year to $16.5 million in Q2 2025, while the trailing twelve-month figure through Mar 2026 was $16.5 million (up 13777.31% YoY) and the FY2025 annual result came in at $16.5 million, changed N/A from the prior year.
- Other Operating Expenses improved to $16.5 million in Q2 2025 per INMB's latest filing, from $119000.0 in the prior quarter.
- Over five years, Other Operating Expenses peaked at $16.5 million in Q2 2025 and troughed at -$425000.0 in Q1 2022.
- A 5-year average of $2.3 million and a median of -$8000.0 in 2021 frame the typical range for Other Operating Expenses.
- The sharpest annual moves came in 2022 and 2025: Other Operating Expenses sank 5212.5% in 2022, then soared 13777.31% in 2025.
- Over 5 years, Other Operating Expenses stood at -$8000.0 in 2021, then tumbled by 5212.5% to -$425000.0 in 2022, then soared by 78.82% to -$90000.0 in 2023, then soared by 232.22% to $119000.0 in 2024, then jumped by 13777.31% to $16.5 million in 2025.
- According to Business Quant data, Other Operating Expenses over the past three periods registered $16.5 million, $119000.0, and -$8000.0 for Q2 2025, Q2 2024, and Q1 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 16.51 Mn |
| Jun 30, 2024 | 119,000.00 |
| Mar 31, 2024 | -8,000.00 |
| Jun 30, 2023 | -90,000.00 |
| Mar 31, 2023 | -113,000.00 |
| Mar 31, 2022 | -425,000.00 |
| Mar 31, 2021 | -8,000.00 |
| Jun 30, 2019 | -1.54 Mn |